08:17 AM EDT, 06/07/2024 (MT Newswires) -- BioCardia ( BCDA ) said Friday that the US Patent Office has granted a patent for the company's radial and transendocardial biotherapeutic delivery catheter through 2036.

The Helix biotherapeutic delivery system is being evaluated in ongoing clinical trials, according to BioCardia ( BCDA ). It relates to medical procedures and systems for substance delivery to the heart through a radial artery and for the intracardiac delivery of cellular aggregates and other materials, the company said.

BioCardia's ( BCDA ) stock climbed more than 44% in recent Friday premarket activity.

Price: 6.3000, Change: +1.93, Percent Change: +44.16